Please assess the completion status of the following clinical trial:

Trial Title: Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal or greater than 18 years.~* To comply with any of the following diagnoses:~* chronic Hepatitis E: HEV RNA detectable in patients with elevated transaminase levels for at least 6 months and / or HEV RNA detectable in two separated determinations by an interval of six months .~* severe acute Hepatitis E: alanine aminotransferase (ALT) levels greater than 10 times the normal limit, with HEV RNA positive, and signs of acute liver injury (International normalized ratio(INR\> 1.5)); or with extrahepatic manifestations or liver failure in patients with previous liver disease.~* Signed informed consent~Exclusion Criteria:~* Terminal illness with a expected life expectancy of less than 6 months~* Patients with contraindications for treatment with Ribavirin:~* pregnancy or lactation.~* Severe hepatic impairment or decompensated cirrhosis.~* hemoglobinopathies (thalassemia, sickle cell anemia).~* history of severe pre-existing cardiac disease, including unstable heart disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: OTHER): Patients will receive ribavirin during 12 weeks
- Group B (Type: OTHER): Patients will receive:~* ribavirin during 12 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is undetectable at week 4 after treatment start (adjust to renal function)~* - ribavirin during 24 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is detectable at week 4 after treatment start (adjust to renal function)

Based on this trial design, predict the completion outcome and termination type (if applicable).